United States burden of melanoma and non-melanoma skin cancer from 1990 to 2019
| Autor: | Alan B. Fleischer, Pushkar Aggarwal, Peter Knabel |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty Skin Neoplasms Time Factors Prevalence Dermatology Disability Evaluation 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Cost of Illness medicine Humans Basal cell carcinoma Melanoma Aged Aged 80 and over Skin Neoplasm business.industry Incidence Mortality rate Incidence (epidemiology) Cancer Middle Aged medicine.disease United States Carcinoma Basal Cell 030220 oncology & carcinogenesis Carcinoma Squamous Cell Female Quality-Adjusted Life Years Skin cancer business |
| Zdroj: | Journal of the American Academy of Dermatology. 85:388-395 |
| ISSN: | 0190-9622 |
| Popis: | Background Skin cancer is the most common cancer worldwide. Objective To evaluate the burden of skin cancer in the US from 1990 to 2019. Methods Age-standardized incidence, prevalence, disability-adjusted life years (DALY), and mortality rates from skin cancer in the US were evaluated from the Global Burden of Disease 2019. Results Incidence, prevalence, DALY, and mortality rates for melanoma per 100,000 persons in 2019 were 17.0, 138, 64.8, and 2.2, respectively; for squamous cell carcinoma, rates were 262, 314, 26.6, and 0.8, respectively; and for basal cell carcinoma, rates were 525, 51.2, 0.2, and zero, respectively. Incidence and prevalence rates of melanoma and non-melanoma skin cancer (NMSC) have increased since 1990, while mortality rates have remained fairly stable. Males have had higher incidence, prevalence, DALY, and mortality rates from melanoma and NMSC every year since 1990. Incidence and prevalence of melanoma was relatively higher in the northern half of the US than in the southern half. Limitations Global Burden of Disease is derived from estimation and mathematical modeling. Conclusions Health care professionals can utilize differences and trends noted in this study to guide allocation of resources to reduce incidence and morbidity from skin cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect